Impact Evidence & Engagement

About Every Cure: 

Every Cure is an AI-driven nonprofit, biotech organization on a mission to save and improve lives by repurposing existing medicines for diseases with significant unmet need. We are working to create a world where every drug is used to treat every disease it possibly can, so that no patient suffers when an existing treatment could help them. Rather than starting with a single disease or drug, we take an “all-vs-all" approach, systematically looking across every FDA-approved drug and every known disease to surface repurposing opportunities most likely to help patients. We are also the first organization to take end-to-end ownership of that process: from identifying promising repurposing opportunities, to validating it in the lab and/or clinic, to working with physicians, payers, and patient advocacy groups to get it to the patients who need it. We are filling a gap left by the current biomedical system, which doesn’t systematically pursue new uses for old drugs. Every Cure pairs AI-driven prediction with rigorous review from our medical team, plus close collaboration with healthcare professionals and patient advocacy groups, to unlock the full potential of existing medicines to treat every disease and every patient we possibly can.  

Inspired by Every Cure’s co-founders' work repurposing drugs for Castleman disease and other rare diseases, Every Cure is advancing repurposed treatments for neglected diseases and has been featured in The New Yorker, The New York Times, USA Today, Good Morning America, Nature, and other news media. Led by a talented leadership team and an outstanding Board of Directors, Every Cure is supported through funding from leading philanthropic organizations like Chan Zuckerberg Initiative, TED’s Audacious Project, as well as the federal agency ARPA-H.  

Our approach: 

• AI-Powered Identification: We use advanced artificial intelligence to analyze the world’s biomedical knowledge and identify FDA-approved drugs that can be repurposed for conditions with unmet needs. This cutting-edge technology enables us to explore new therapeutic possibilities efficiently.  
• Open-Source Commitment: Many of our methods' code, quality-checking tools, and knowledge graph pipeline are open-source, and our drug list, disease list, and knowledge graph-based drug-disease scores are freely available. We aim to foster collaboration and transparency within the scientific community and unlock the potential for discovering new treatments.